Immunoassay and clinical chemistry are the two largest segments of the IVD market, collectively accounting for approximately 50% of global IVD revenues. Immunoassay holds the largest technology share at approximately 35% of the total IVD market in 2025. Reagents and kits hold the largest product share at approximately 69% of the market. The consolidation of immunoassay and clinical chemistry analyzers onto integrated core laboratory platforms — combining both disciplines on a single automation track — is the dominant competitive dynamic, with Roche's cobas series, Abbott's Alinity, Siemens Healthineers' Atellica, and Beckman Coulter's DxC competing for high-volume laboratory placements. Menu breadth, turnaround time, and reagent rental financing terms are the primary competitive battlegrounds.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Immunoassay and Clinical Chemistry Market Size and Forecast 2025-2030 by Segment
• Core Laboratory Consolidation — Integrated Platforms and Total Lab Automation
• Immunoassay Technologies — Chemiluminescence, ELISA, CLIA, and Fluorescence
• High-Sensitivity Assays — Troponin, Procalcitonin, and High-Sensitivity CRP
• Clinical Chemistry Menu — Metabolic, Hepatic, Renal, and Therapeutic Drug Monitoring
• Reagent Rental and Placement Financing — Market Size and Business Model Analysis
• Menu Expansion Strategies — New Analytes, Specialty Testing, and Automation Integration
• Competitive Landscape — Roche, Abbott, Siemens Healthineers, Beckman Coulter, and DiaSorin
• Investment and Partnership Opportunities
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Highest-priority opportunities
- Competitive landscape summary
- Strategic recommendations
2. Market Overview
- Market definition, scope and segmentation
- Key demand drivers and restraints
- Regulatory environment
3. Core Laboratory Consolidation
- Integrated platform competition — Roche, Abbott, Siemens, Beckman Coulter
- Total lab automation and platform bundling
- Reagent rental contract dynamics and competitive displacement
4. Immunoassay Technologies
- Chemiluminescence and electrochemiluminescence
- High-sensitivity assay development and adoption
- Specialty immunoassay — endocrinology, TDM, and autoimmune
5. Clinical Chemistry
- Core clinical chemistry panels — metabolic, hepatic, renal
- Therapeutic drug monitoring
- Clinical chemistry menu expansion onto integrated platforms
6. Reagent Rental and Commercial Models
- Reagent rental financial structure and risk allocation
- Contract terms and competitive displacement strategy
- Emerging commercial models — digital services and connectivity
7. Competitive Landscape
- Roche, Abbott, Siemens Healthineers, Beckman Coulter, and DiaSorin
- Emerging competitors from China and specialty suppliers
- M&A and partnership activity 2023-2025
8. Regional Market Analysis
- 8.1 North America (U.S., Canada, Mexico)
- 8.2 Europe (38 countries)
- 8.3 Asia-Pacific (18 countries)
- 8.4 Latin America (22 countries)
- 8.5 Middle East (11 countries)
- 8.6 Africa and Rest of World
9. Strategic Conclusions and Recommendations
- Highest-priority opportunities by segment and region
- Market entry and expansion strategies
- M&A, partnership and investment priorities
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. Core Laboratory Platform Competition — Roche, Abbott, Siemens, Beckman Coulter 2025
Table 2. Immunoassay Technology Comparison — Chemiluminescence and Electrochemiluminescence 2025
Table 3. High-Sensitivity Assay Landscape — Troponin, Procalcitonin, and hsCRP 2025
Table 4. Specialty Immunoassay — Endocrinology, TDM, and Autoimmune Testing 2025
Table 5. Clinical Chemistry — Menu Comparison by Platform 2025
Table 6. Reagent Rental — Financial Structure and Contract Analysis 2025
Table 7. Leading Suppliers and Competitive Positioning 2025
Table 8. M&A and Partnership Activity 2023-2025
Table 9. Regional Market Analysis 2025
Table 10. Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
